Literature DB >> 21883694

miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer.

Akihiko Tsuchida1, Shinichiro Ohno, Weihong Wu, Nariso Borjigin, Koji Fujita, Tastuya Aoki, Shinobu Ueda, Masakatsu Takanashi, Masahiko Kuroda.   

Abstract

MicroRNAs (miRNAs) belong to a class of endogenously expressed non-coding small RNAs that function primarily as gene regulators. Growing evidence suggests that miRNAs play a significant role in tumor development, making them potential biomarkers for cancer diagnosis and prognosis. The miR-17-92 cluster has emerged as an important locus, being highly overexpressed in several cancers in association with cancer development and progression. The miR-17-92 miRNA cluster generates a single polycistronic primary transcript that yields six mature miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a. In colon cancer development, the pathophysiologic roles of these transcripts and their targets are largely unknown. In the present study, we performed copy number analyses of the six miRNAs transcribed from the miR-17-92 cluster in colon tumor tissues. We determined that miR-92a was transcribed at higher levels than the other five miRNAs in both adenomas and carcinoma. In addition, miR-92a directly targeted the anti-apoptotic molecule BCL-2-interacting mediator of cell death (BIM) in colon cancer tissues. An anti-miR-92a antagomir induced apoptosis of colon cancer-derived cell lines. These data indicate that miR-92a plays a pivotal role in the development of colorectal carcinoma.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883694     DOI: 10.1111/j.1349-7006.2011.02081.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  106 in total

1.  Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.

Authors:  Tong Zhou; Guangjun Zhang; Zuoliang Liu; Shusen Xia; Hongpeng Tian
Journal:  Int J Colorectal Dis       Date:  2012-07-07       Impact factor: 2.571

2.  High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFβ in thyroid follicular cells.

Authors:  Cesar Seigi Fuziwara; Edna Teruko Kimura
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

3.  MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN.

Authors:  Guangjun Zhang; He Zhou; Huaxu Xiao; Zuoliang Liu; Hongpeng Tian; Tong Zhou
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

Review 4.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

Review 5.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells.

Authors:  Haifeng Wang; Changxing Ke; Xingyong Ma; Qinghua Zhao; Mingying Yang; Wei Zhang; Jiansong Wang
Journal:  Tumour Biol       Date:  2016-11-09

7.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

8.  MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR.

Authors:  Jian-Hua Duan; Long Fang
Journal:  Tumour Biol       Date:  2014-08-06

Review 9.  Role of microRNAs in the immune system, inflammation and cancer.

Authors:  Jennifer Raisch; Arlette Darfeuille-Michaud; Hang Thi Thu Nguyen
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

10.  Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.

Authors:  Jinhua Zhang; Gottumakkala S Raju; David W Chang; Shu-Hong Lin; Zhinan Chen; Xifeng Wu
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.